The Global Parkinson’s disease market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Pharmaceutical firms are developing new and improved therapies for Parkinson’s disease (PD). Recently, there have been some major product launches in Parkinson’s disease. For instance, in February 2022, Avion Pharmaceuticals LLC announced the commercial launch of DHIVY, the first and only carbidopa/ levodopa (CD/LD) fractional tablet designed to be divided. Avion gained approval for DHIVY from the FDA in Nov 2021. This unique design enables more precise medication for those with Parkinson’s disease (PD). Also, government funding for research and massive utilization of L-Dopa, asymptomatic dopamine replacement treatment, and the nigrostriatal system expects a boost to the market in the coming years.
A full report of Parkinson’s Disease Drug Market is available at: https://www.omrglobal.com/industry-reports/parkinsons-disease-drug
The shifting of research activities from symptomatic treatment to Parkinson’s disorder modifying treatment will create growth for Parkinson’s disease treatment industry over the forthcoming years. For instance, Kyowa Kirin Co Ltd a Japanese Pharmaceutical and biotechnology company announced the U.S. Food and Drug Administration (FDA) approval for medicine NOURIANZ (istradefylline). For instance, in Feb 2020, Sun Pharma launched severe nodular acne management capsules in the US. It is launched for patients who are below 12 years of age or older. It can be taken with or without food.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/parkinsons-disease-drug
Market Coverage
- The market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered- By Mechanism of Action
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Land- AbbVie Inc., Merck & Co. Inc., Boehringer Ingelheim GmbH, GlaxoSmithKline Plc, Bausch Health Companies Inc., Cipla Inc., Daiichi Sankyo Espha Co., Ltd., and others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impact the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Parkison’s Disease Drug Market Report Segment
By Mechanism of Action
- Dopamine Agonists
- Anticholinergic
- MAO-B Inhibitors
- Amantadine
- Carbidopa-levodopa
- COMT Inhibitors
- Others
